A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Zhao, Hongyun
Zhang, Zhonghan
Luo, Fan
Ma, Yuxiang
Fang, Wenfeng
Yang, Yunpeng
Zhang, Yang
Huang, Yan
Zhang, Li
机构：
[1] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS9116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9116
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
    Han, Baohui
    Xiu, Qingyu
    Wang, Huimin
    Shen, Jie
    Gu, Aiqin
    Luo, Yi
    Bai, Chunxue
    Guo, Shuliang
    Liu, Wenchao
    Zhuang, Zhixiang
    Zhang, Yang
    Zhao, Yizhuo
    Jiang, Liyan
    Zhou, Jianying
    Jin, Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1104 - 1109
  • [42] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [43] A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
    Zhang, Li
    Shi, Meiqi
    Huang, Cheng
    Liu, Xiaoqing
    Xiong, Jian Ping
    Chen, Gongyan
    Liu, Wei
    Liu, Wenchao
    Zhang, Yiping
    Li, Kai
    Yu, Hao
    Jiang, Haoyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma
    Benson, Al B., III
    Wainberg, Zev A.
    Hecht, J. Randolph
    Vyushkov, Dmitry
    Dong, Hua
    Bendell, Johanna
    Kudrik, Fred
    ONCOLOGIST, 2017, 22 (03): : 241 - +
  • [45] A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
    Si, Xiaoyan
    Wang, Jinwan
    Cheng, Ying
    Shi, Jianhua
    Cui, Liying
    Zhang, Helong
    Huang, Yunchao
    Liu, Wei
    Chen, Lei
    Zhu, Jiang
    Zhang, Shucai
    Li, Wei
    Sun, Yan
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Yang, Lin
    Zhang, Li
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [46] Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Mok, Tony S. K.
    Wu, Yi-Long
    Yu, Chong-Jen
    Zhou, Caicun
    Chen, Yuh-Min
    Zhang, Li
    Ignacio, Jorge
    Liao, Meilin
    Srimuninnimit, Vichien
    Boyer, Michael J.
    Chua-Tan, Marina
    Sriuranpong, Virote
    Sudoyo, Aru W.
    Jin, Kate
    Johnston, Michael
    Chui, Winsome
    Lee, Jin-Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5080 - 5087
  • [47] The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
    Spigel, David R.
    Edelman, Martin J.
    Mok, Tony
    O'Byrne, Kenneth John
    Paz-Ares, Luis
    Yu, Wei
    Rittweger, Karen
    Thurm, Holger C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
    Ready, Neal
    Karaseva, Nina A.
    Orlov, Sergey V.
    Luft, Alexander V.
    Popovych, Olexandr
    Holmlund, Jon T.
    Wood, Brian A.
    Leopold, Lance
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 781 - 785
  • [49] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [50] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)
    Surmont, V. F.
    Gaafar, R. M.
    Scagliotti, G. V.
    van Klaveren, R. J.
    Papamichael, D.
    Hasan, B.
    Torri, V.
    van Meerbeeck, J. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124
12345